HUMAN HEALTH
ABI is developing human health products including therapeutics and oral vaccine candidates. Products currently under development include oral vaccine candidates for Hepatitis B, COVID-19, Valley Fever, and Lyme Disease.
Contact us to discuss collaborating on these or other human health related products.
References
Egelkrout, Erin, et al. "Effect of Fusion to the LTB Carrier Protein on Coronavirus Spike Protein Vaccine Candidates Produced in Maize." Viruses 17.1 (2024): 7.
Hayden, Celine A., et al. "Production of highly concentrated, heat‐stable hepatitis B surface antigen in maize." Plant biotechnology journal 10.8 (2012): 979-984.
Hayden, Celine A., et al. "Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen." Vaccine 30.19 (2012): 2937-2942.
Hayden, Celine A., et al. "Supercritical fluid extraction provides an enhancement to the immune response for orally-delivered hepatitis B surface antigen." Vaccine 32.11 (2014): 1240-1246.
Hayden, Celine A., et al. "Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses." Vaccine 33.25 (2015): 2881-2886.
Hayden, Celine A., et al. "Co-administration of injected and oral vaccine candidates elicits improved immune responses over either route alone." Vaccines 8.1 (2020): 37.
Hayden, Celine A., et al. "Maize-produced Ag2 as a subunit vaccine for valley fever." The Journal of infectious diseases 220.4 (2019): 615-623.